Literature DB >> 12765

Piroxicam, a novel anti-inflammatory agent.

E H Wiseman, Y H Chang, J G Lombardino.   

Abstract

Piroxicam (CP-16 171) is a potent acidic anti-inflammatory agent structurally distinct from the current agents such as indometacin, phenylbutazone or naproxen. Pharmacokinetic studies indicate a longer plasma half-ife for piroxicam than for these agents. Potency in the range of indometacin is observed when piroxicam is tested in the carrageenan rat paw edema model. This activity is not dependent on an intact adrenocorticoid system. The high potency, long half-life and absence of cardiovascular or cental nervous system effects have encouraged clinical trial of piroxicam.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 12765     DOI: 10.1002/chin.197641380

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  15 in total

1.  Comparative bioavailability of two different rectal preparations of piroxicam in man.

Authors:  S Benkö; G Grézal; E Nagy; I Klebovich
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  A re-evaluation of the HSA-piroxicam interaction.

Authors:  F Brée; S Urien; P Nguyen; P Riant; E Albengres; J P Tillement
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Oct-Dec       Impact factor: 2.441

3.  The analgetic properties of piroxicam in animals and correlation with experimentally determined plasma levels.

Authors:  G M Milne; T M Twomey
Journal:  Agents Actions       Date:  1980-04

4.  In vitro and in vivo effects of piroxicam on rat polymorphonuclear responsiveness after induction of two acute non-specific inflammatory reactions.

Authors:  D P Huy; M Roch-Arveiller; M Lenoir; O Muntaner; A Thuret; J P Giroud
Journal:  Agents Actions       Date:  1986-06

Review 5.  Piroxicam. A reappraisal of its pharmacology and therapeutic efficacy.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-10       Impact factor: 9.546

6.  Incidence of gastric ulcers by indomethacin and piroxicam in rats.

Authors:  C N Aguwa
Journal:  Arch Toxicol       Date:  1985-01       Impact factor: 5.153

7.  The topical anti-inflammatory effects of piroxicam in rodents.

Authors:  D L Larson; J G Lombardino
Journal:  Agents Actions       Date:  1980-06

8.  Phase I trial of piroxicam in 62 dogs bearing naturally occurring tumors.

Authors:  D W Knapp; R C Richardson; G D Bottoms; R Teclaw; T C Chan
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

9.  A comparison of the carrageenan edema test and ultraviolet light-induced erythema test as predictors of the clinical dose in rheumatoid arthritis.

Authors:  I G Otterness; E H Wiseman; D J Gans
Journal:  Agents Actions       Date:  1979-06

10.  Effects of indomethacin, piroxicam and selected prostanoids on gastric acid secretion by the rat isolated gastric mucosa.

Authors:  J J Reeves; R Stables
Journal:  Br J Pharmacol       Date:  1985-11       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.